5c0d: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==HLA-A02 carrying AQWGPDPAAA== | ==HLA-A02 carrying AQWGPDPAAA== | ||
<StructureSection load='5c0d' size='340' side='right' caption='[[5c0d]], [[Resolution|resolution]] 1.68Å' scene=''> | <StructureSection load='5c0d' size='340' side='right'caption='[[5c0d]], [[Resolution|resolution]] 1.68Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5c0d]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5C0D OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5C0D FirstGlance]. <br> | <table><tr><td colspan='2'>[[5c0d]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5C0D OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5C0D FirstGlance]. <br> | ||
</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5c06|5c06]], [[5c07|5c07]], [[5c08|5c08]], [[5c09|5c09]], [[5c0a|5c0a]], [[5c0b|5c0b]], [[5c0c|5c0c]], [[5c0e|5c0e]], [[5c0f|5c0f]], [[5c0g|5c0g]], [[5c0i|5c0i]], [[5c0j|5c0j]], [[3utp|3utp]], [[3utq|3utq]], [[3uts|3uts]], [[3utt|3utt]], [[5hyj|5hyj]], [[5c0h|5c0h]]</td></tr> | </td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5c06|5c06]], [[5c07|5c07]], [[5c08|5c08]], [[5c09|5c09]], [[5c0a|5c0a]], [[5c0b|5c0b]], [[5c0c|5c0c]], [[5c0e|5c0e]], [[5c0f|5c0f]], [[5c0g|5c0g]], [[5c0i|5c0i]], [[5c0j|5c0j]], [[3utp|3utp]], [[3utq|3utq]], [[3uts|3uts]], [[3utt|3utt]], [[5hyj|5hyj]], [[5c0h|5c0h]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5c0d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5c0d OCA], [http://pdbe.org/5c0d PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5c0d RCSB], [http://www.ebi.ac.uk/pdbsum/5c0d PDBsum]</span></td></tr> | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">HLA-A, HLAA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), B2M, CDABP0092, HDCMA22P ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5c0d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5c0d OCA], [http://pdbe.org/5c0d PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5c0d RCSB], [http://www.ebi.ac.uk/pdbsum/5c0d PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5c0d ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Disease == | == Disease == | ||
Line 20: | Line 21: | ||
</div> | </div> | ||
<div class="pdbe-citations 5c0d" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5c0d" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Beta-2 microglobulin 3D structures|Beta-2 microglobulin 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | |||
[[Category: Large Structures]] | |||
[[Category: Bulek, A M]] | [[Category: Bulek, A M]] | ||
[[Category: Cole, D K]] | [[Category: Cole, D K]] |
Revision as of 14:06, 18 March 2020
HLA-A02 carrying AQWGPDPAAAHLA-A02 carrying AQWGPDPAAA
Structural highlights
Disease[B2MG_HUMAN] Defects in B2M are the cause of hypercatabolic hypoproteinemia (HYCATHYP) [MIM:241600]. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin, probably due to rapid degradation.[1] Note=Beta-2-microglobulin may adopt the fibrillar configuration of amyloid in certain pathologic states. The capacity to assemble into amyloid fibrils is concentration dependent. Persistently high beta(2)-microglobulin serum levels lead to amyloidosis in patients on long-term hemodialysis.[2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Function[1A02_HUMAN] Involved in the presentation of foreign antigens to the immune system. [B2MG_HUMAN] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system. Publication Abstract from PubMedThe cross-reactivity of T cells with pathogen- and self-derived peptides has been implicated as a pathway involved in the development of autoimmunity. However, the mechanisms that allow the clonal T cell antigen receptor (TCR) to functionally engage multiple peptide-major histocompatibility complexes (pMHC) are unclear. Here, we studied multiligand discrimination by a human, preproinsulin reactive, MHC class-I-restricted CD8+ T cell clone (1E6) that can recognize over 1 million different peptides. We generated high-resolution structures of the 1E6 TCR bound to 7 altered peptide ligands, including a pathogen-derived peptide that was an order of magnitude more potent than the natural self-peptide. Evaluation of these structures demonstrated that binding was stabilized through a conserved lock-and-key-like minimal binding footprint that enables 1E6 TCR to tolerate vast numbers of substitutions outside of this so-called hotspot. Highly potent antigens of the 1E6 TCR engaged with a strong antipathogen-like binding affinity; this engagement was governed though an energetic switch from an enthalpically to entropically driven interaction compared with the natural autoimmune ligand. Together, these data highlight how T cell cross-reactivity with pathogen-derived antigens might break self-tolerance to induce autoimmune disease. Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity.,Cole DK, Bulek AM, Dolton G, Schauenberg AJ, Szomolay B, Rittase W, Trimby A, Jothikumar P, Fuller A, Skowera A, Rossjohn J, Zhu C, Miles JJ, Peakman M, Wooldridge L, Rizkallah PJ, Sewell AK J Clin Invest. 2016 May 16. pii: 85679. doi: 10.1172/JCI85679. PMID:27183389[15] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|